UNSPSC 51372606: Enadoline hydrochloride

This classification denotes an opioid receptor agonist C24H32N2O3.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 086I9HO04E, chemically known as n-methyl-n-((5r,7s,8s)-7-(1-pyrrolidinyl)-1-oxaspiro(4.5)dec-8-yl)-4-benzofuranacetamide monohydrochloride, but more generally known as enadoline hydrochloride, which bears US NIH Compound Identifier 60767. Most nations, for tariff and trade purposes, schedule enadoline hydrochloride under HS 29349990 and SITC 51579.

As of Q4 2014, ENADOLINE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Enadoline hydrochloride bears US NLM identifiers UMLS ID C2825260 and NCI Concept Code C80577. SMILES: CN([C@H]1CC[C@@]2(CCCO2)C[C@@H]1N3CCCC3)C(=O)CC4CCCC5C4CCO5.CL.

UNSPSC 51372606 Enadoline hydrochloride is a Commodity code that captures pharmaceutical products, though recent state and local procurement activity under this code shows limited direct solicitations for enadoline specifically. Instead, issuing bodies are buying naloxone and other pharmaceutical products through broader generic pharmaceutical and opioid-response procurement vehicles. State and local governments procuring under related pharmaceutical codes are seeking products for public health initiatives, community health programs, and emergency response systems, with vendors required to meet FDA compliance, cGMP certification, Drug Supply Chain Security Act adherence, and specific insurance and employment verification requirements. Issuing bodies include county health departments, state health and human services commissions, and cooperative purchasing alliances spanning multiple jurisdictions. Contracts typically include probationary periods, performance penalties, and fixed-fee or competitive pricing models with quarterly or ongoing delivery schedules.

Recent activity appears concentrated in Florida and Minnesota, with multistate reach through cooperative purchasing vehicles. Seminole County, Florida issued IFB60459723LAS in June 2026 seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries, response due July 26, 2023. The Texas Health and Human Services Commission posted RFI HHS0017013 in April 2026 to gather vendor capabilities for direct-to-manufacturer prescription programs outside traditional pharmacy benefit manager arrangements. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) issued an RFP in January 2026 for generic multi-source pharmaceuticals and OTC products distributed across participating state and local facilities in Minnesota and Oregon, with proposals due March 26, 2026 and contract effectiveness July 1, 2026. Vendors must work with authorized wholesalers and demonstrate pricing flexibility across multiple formats with a 3 percent administrative fee. The code shows modest recent activity with no exclusive concentration in a single state or jurisdiction type.